Kyverna Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Kyverna Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Kyverna Therapeutics, Inc. Common Stock (KYTX) has a cash flow conversion efficiency ratio of -0.213x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.60 Million) by net assets ($195.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kyverna Therapeutics, Inc. Common Stock (2021–2025)
Cash flow conversion efficiency of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025. This chart illustrates how Kyverna Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Kyverna Therapeutics, Inc. Common Stock (KYTX) stock price for real-time trading data and today's change.
Kyverna Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Kyverna Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kyverna Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyverna Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Kyverna Therapeutics, Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Barings Corporate Investors
NYSE:MCI
|
0.014x |
|
Seanergy Maritime Holdings Corp
NASDAQ:SHIP
|
0.101x |
|
Magna Mining Inc
V:NICU
|
-0.091x |
|
Beijing Kaiwen Education Technology Co Ltd
SHE:002659
|
0.034x |
|
Jinhong Fashion Group Co Ltd
SHG:603518
|
-0.014x |
|
Guangzhou Jinzhong Auto Parts Manufacturing Co. Ltd.
SHE:301133
|
-0.042x |
|
Talgo SA
MC:TLGO
|
-0.761x |
|
Energiekontor AG
F:EKT
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Kyverna Therapeutics, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025. Review Kyverna Therapeutics, Inc. Common Stock free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $232.28 Million | $-153.71 Million | -0.662x | -54.41% |
| 2024-12-31 | $266.59 Million | $-114.25 Million | -0.429x | +59.79% |
| 2023-12-31 | $49.18 Million | $-52.41 Million | -1.066x | -37.75% |
| 2022-12-31 | $46.68 Million | $-36.11 Million | -0.774x | -261.52% |
| 2021-12-31 | $-46.25 Million | $-22.16 Million | 0.479x | -- |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product ca… Read more